TY - JOUR
T1 - Proximity-Induced Nucleic Acid Degrader (PINAD) approach to targeted RNA degradation using small molecules
AU - Mikutis, Sigitas
AU - Rebelo, Maria
AU - Yankova, Eliza
AU - Gu, Muxin
AU - Tang, Cong
AU - Coelho, Ana R.
AU - Yang, Mo
AU - Hazemi, Madoka E.
AU - Pires de Miranda, Marta
AU - Eleftheriou, Maria
AU - Robertson, Max
AU - Vassiliou, George S.
AU - Adams, David J.
AU - Simas, J. Pedro
AU - Corzana, Francisco
AU - Schneekloth, John S.
AU - Tzelepis, Konstantinos
AU - Bernardes, Gonçalo J.L.
N1 - Publisher Copyright:
© 2023 American Chemical Society. All rights reserved.
PY - 2023/5/24
Y1 - 2023/5/24
N2 - Nature has evolved intricate machinery to target and degrade RNA, and some of these molecular mechanisms can be adapted for therapeutic use. Small interfering RNAs and RNase H-inducing oligonucleotides have yielded therapeutic agents against diseases that cannot be tackled using protein-centered approaches. Because these therapeutic agents are nucleic acid-based, they have several inherent drawbacks which include poor cellular uptake and stability. Here we report a new approach to target and degrade RNA using small molecules, proximity-induced nucleic acid degrader (PINAD). We have utilized this strategy to design two families of RNA degraders which target two different RNA structures within the genome of SARS-CoV-2: G-quadruplexes and the betacoronaviral pseudoknot. We demonstrate that these novel molecules degrade their targets using in vitro, in cellulo, and in vivo SARS-CoV-2 infection models. Our strategy allows any RNA binding small molecule to be converted into a degrader, empowering RNA binders that are not potent enough to exert a phenotypic effect on their own. PINAD raises the possibility of targeting and destroying any disease-related RNA species, which can greatly expand the space of druggable targets and diseases.
AB - Nature has evolved intricate machinery to target and degrade RNA, and some of these molecular mechanisms can be adapted for therapeutic use. Small interfering RNAs and RNase H-inducing oligonucleotides have yielded therapeutic agents against diseases that cannot be tackled using protein-centered approaches. Because these therapeutic agents are nucleic acid-based, they have several inherent drawbacks which include poor cellular uptake and stability. Here we report a new approach to target and degrade RNA using small molecules, proximity-induced nucleic acid degrader (PINAD). We have utilized this strategy to design two families of RNA degraders which target two different RNA structures within the genome of SARS-CoV-2: G-quadruplexes and the betacoronaviral pseudoknot. We demonstrate that these novel molecules degrade their targets using in vitro, in cellulo, and in vivo SARS-CoV-2 infection models. Our strategy allows any RNA binding small molecule to be converted into a degrader, empowering RNA binders that are not potent enough to exert a phenotypic effect on their own. PINAD raises the possibility of targeting and destroying any disease-related RNA species, which can greatly expand the space of druggable targets and diseases.
UR - http://www.scopus.com/inward/record.url?scp=85156240026&partnerID=8YFLogxK
U2 - 10.1021/acscentsci.3c00015
DO - 10.1021/acscentsci.3c00015
M3 - Article
C2 - 37252343
AN - SCOPUS:85156240026
SN - 2374-7943
VL - 9
SP - 892
EP - 904
JO - ACS Central Science
JF - ACS Central Science
IS - 5
ER -